|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Zantac
|
|
gptkbp:class
|
H2 antagonist
|
|
gptkbp:clinical_trial
|
50% to 60%
ranitidine efficacy study
ranitidine safety study
|
|
gptkbp:contraindication
|
allergy to ranitidine
|
|
gptkbp:current_use
|
peptic ulcer disease
Zollinger-Ellison syndrome
gastroesophageal reflux disease
|
|
gptkbp:dosage_form
|
oral tablet
|
|
gptkbp:effective_date
|
gptkb:1983
withdrawn
|
|
gptkbp:first_released
|
gptkb:2019
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:has_ability
|
75 mg
|
|
gptkbp:healthcare
|
gptkb:battle
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Zantac 75
|
|
gptkbp:ingredients
|
gptkb:ranitidine
C13 H12 N4 O2 S
|
|
gptkbp:interacts_with
|
gptkb:itraconazole
gptkb:ketoconazole
gptkb:procainamide
gptkb:theophylline
gptkb:warfarin
|
|
gptkbp:is_atype_of
|
A02 B A02
|
|
gptkbp:is_used_for
|
treatment of heartburn
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:marketed_as
|
gptkb:Zantac
|
|
gptkbp:packaging
|
blister pack
|
|
gptkbp:previous_name
|
gptkb:ranitidine
|
|
gptkbp:replaced_by
|
potential carcinogenic risk
|
|
gptkbp:requires
|
over-the-counter
|
|
gptkbp:side_effect
|
dizziness
headache
nausea
diarrhea
constipation
|
|
gptkbp:storage
|
store at room temperature
|
|
gptkbp:type_of
|
66357-35-5
|